 Alastair Robertson
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenergic beta-Antagonists | 8 | 2012 | 298 | 0.590 |
Why?
| | Propanolamines | 6 | 2012 | 93 | 0.480 |
Why?
| | Receptors, Adrenergic, alpha-2 | 3 | 2012 | 15 | 0.300 |
Why?
| | Heart Failure | 10 | 2012 | 1962 | 0.280 |
Why?
| | Receptors, Adrenergic, beta-1 | 2 | 2012 | 53 | 0.210 |
Why?
| | Heart-Assist Devices | 1 | 2008 | 486 | 0.210 |
Why?
| | Heart Transplantation | 1 | 2008 | 661 | 0.210 |
Why?
| | Polymorphism, Genetic | 3 | 2012 | 629 | 0.180 |
Why?
| | Enoximone | 2 | 2007 | 15 | 0.140 |
Why?
| | Cardiotonic Agents | 2 | 2007 | 126 | 0.130 |
Why?
| | Survival Rate | 5 | 2010 | 1679 | 0.110 |
Why?
| | Torsades de Pointes | 2 | 2003 | 17 | 0.110 |
Why?
| | Norepinephrine | 2 | 2012 | 205 | 0.110 |
Why?
| | Ventricular Fibrillation | 1 | 2012 | 51 | 0.110 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 105 | 0.100 |
Why?
| | Methadone | 2 | 2003 | 73 | 0.100 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 149 | 0.100 |
Why?
| | Clinical Trials Data Monitoring Committees | 1 | 2010 | 5 | 0.090 |
Why?
| | Hospital Records | 1 | 2010 | 11 | 0.090 |
Why?
| | Cardiomyopathy, Dilated | 2 | 2003 | 339 | 0.090 |
Why?
| | Research Personnel | 1 | 2010 | 155 | 0.080 |
Why?
| | Middle Aged | 13 | 2012 | 27170 | 0.080 |
Why?
| | Ventricular Function, Right | 2 | 2006 | 261 | 0.070 |
Why?
| | Ventricular Function | 1 | 2006 | 57 | 0.070 |
Why?
| | Stroke Volume | 4 | 2012 | 514 | 0.070 |
Why?
| | Myocardial Contraction | 1 | 2007 | 328 | 0.070 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2005 | 82 | 0.070 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 82 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2012 | 1233 | 0.060 |
Why?
| | Male | 17 | 2012 | 56660 | 0.060 |
Why?
| | Hospitalization | 2 | 2010 | 1762 | 0.060 |
Why?
| | Ventricular Function, Left | 3 | 2012 | 470 | 0.060 |
Why?
| | Female | 16 | 2012 | 60631 | 0.060 |
Why?
| | Hypertension, Pulmonary | 2 | 2006 | 1771 | 0.060 |
Why?
| | Nuclear Lamina | 1 | 2003 | 10 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2003 | 55 | 0.050 |
Why?
| | Retrospective Studies | 6 | 2012 | 12823 | 0.050 |
Why?
| | Long QT Syndrome | 1 | 2003 | 61 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2006 | 1588 | 0.050 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2003 | 111 | 0.050 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2002 | 133 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2004 | 575 | 0.050 |
Why?
| | Treatment Outcome | 6 | 2012 | 9256 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2003 | 299 | 0.050 |
Why?
| | Gene Expression | 2 | 2006 | 1466 | 0.050 |
Why?
| | Humans | 18 | 2012 | 117048 | 0.040 |
Why?
| | Myocytes, Cardiac | 1 | 2003 | 472 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2007 | 1889 | 0.040 |
Why?
| | Myocardium | 1 | 2002 | 944 | 0.040 |
Why?
| | Adult | 9 | 2012 | 31003 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2012 | 1670 | 0.030 |
Why?
| | Hemodynamics | 3 | 2006 | 982 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2002 | 792 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1458 | 0.030 |
Why?
| | Heart Ventricles | 2 | 2012 | 728 | 0.030 |
Why?
| | Administration, Oral | 2 | 2007 | 744 | 0.030 |
Why?
| | Aged | 6 | 2012 | 19356 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2003 | 2227 | 0.030 |
Why?
| | Homozygote | 1 | 2012 | 188 | 0.030 |
Why?
| | Heterozygote | 1 | 2012 | 256 | 0.030 |
Why?
| | Area Under Curve | 1 | 2012 | 285 | 0.030 |
Why?
| | Follow-Up Studies | 3 | 2007 | 4507 | 0.030 |
Why?
| | Phenotype | 3 | 2006 | 2891 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 513 | 0.020 |
Why?
| | Aged, 80 and over | 3 | 2009 | 6453 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2012 | 155 | 0.020 |
Why?
| | Bayes Theorem | 1 | 2012 | 341 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 825 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2003 | 1001 | 0.020 |
Why?
| | Electrocardiography | 2 | 2003 | 548 | 0.020 |
Why?
| | Prognosis | 2 | 2007 | 3390 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2007 | 50 | 0.020 |
Why?
| | Genotype | 2 | 2003 | 1854 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 1877 | 0.020 |
Why?
| | Pain | 2 | 2003 | 719 | 0.020 |
Why?
| | Psychological Tests | 1 | 2007 | 123 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2007 | 151 | 0.020 |
Why?
| | United States | 3 | 2010 | 12379 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 376 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2010 | 795 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2005 | 57 | 0.020 |
Why?
| | Health Surveys | 1 | 2007 | 443 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 723 | 0.020 |
Why?
| | Models, Biological | 1 | 2012 | 1689 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2006 | 299 | 0.020 |
Why?
| | Cardiomegaly | 1 | 2006 | 166 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2003 | 2632 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2005 | 248 | 0.020 |
Why?
| | Psychometrics | 1 | 2007 | 602 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 761 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 965 | 0.010 |
Why?
| | Hypokalemia | 1 | 2003 | 30 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2006 | 750 | 0.010 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 104 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2003 | 54 | 0.010 |
Why?
| | Heroin Dependence | 1 | 2002 | 19 | 0.010 |
Why?
| | Angiotensin II | 1 | 2003 | 107 | 0.010 |
Why?
| | Calcium-Transporting ATPases | 1 | 2002 | 35 | 0.010 |
Why?
| | Ventricular Myosins | 1 | 2002 | 32 | 0.010 |
Why?
| | Metoprolol | 1 | 2002 | 37 | 0.010 |
Why?
| | Probability | 1 | 2003 | 296 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 392 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2003 | 373 | 0.010 |
Why?
| | Adolescent | 3 | 2006 | 18213 | 0.010 |
Why?
| | Carbazoles | 1 | 2002 | 79 | 0.010 |
Why?
| | Pedigree | 1 | 2003 | 475 | 0.010 |
Why?
| | Cadherins | 1 | 2003 | 180 | 0.010 |
Why?
| | Canada | 1 | 2002 | 337 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 6389 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2003 | 475 | 0.010 |
Why?
| | Exercise Test | 1 | 2004 | 541 | 0.010 |
Why?
| | Pulmonary Circulation | 1 | 2003 | 406 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2004 | 1105 | 0.010 |
Why?
| | Myosin Heavy Chains | 1 | 2002 | 192 | 0.010 |
Why?
| | Blotting, Western | 1 | 2003 | 1172 | 0.010 |
Why?
| | Research Design | 1 | 2005 | 962 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2003 | 661 | 0.010 |
Why?
| | Child, Preschool | 2 | 2003 | 9322 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2032 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1657 | 0.010 |
Why?
| | Prevalence | 1 | 2003 | 2300 | 0.010 |
Why?
| | Chronic Disease | 1 | 2002 | 1619 | 0.010 |
Why?
| | Opioid-Related Disorders | 1 | 2003 | 426 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2007 | 4661 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2003 | 1730 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2003 | 2633 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3121 | 0.010 |
Why?
| | Risk Assessment | 1 | 2003 | 3021 | 0.010 |
Why?
| | Cohort Studies | 1 | 2003 | 5050 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2003 | 5170 | 0.010 |
Why?
| | Infant | 1 | 2003 | 8121 | 0.010 |
Why?
| | Risk Factors | 1 | 2002 | 8873 | 0.010 |
Why?
| | Child | 1 | 2003 | 18876 | 0.000 |
Why?
|
|
Robertson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|